We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Xenetic's IND to Start Phase II Virexxa Study Accepted in U.S.
Read MoreHide Full Article
Xenetic Biosciences, Inc. (XBIO - Free Report) announced that the FDA has accepted the company’s Investigational New Drug (IND) application to initiate a phase II study on Virexxa (sodium cridanimod) in endometrial cancer.
The study will evaluate Virexxa, in conjunction with progestin therapy, for the treatment of endometrial cancer in women with recurrent or persistent disease who have failed progestin monotherapy.
The primary objective of the study is the assessment of anti-tumor activity of Virexxa, while secondary objectives include the evaluation of additional efficacy, pharmacokinetic and safety/tolerability parameters of the candidate.
Note that, Virexxa is currently being evaluated in phase II study in patients with documented evidence of progesterone receptor-negative endometrial cancer as determined by tumor biopsy. The candidate enjoys Orphan drug status in the U.S. for the treatment of progesterone receptor-negative endometrial cancer.
We remind investors that in Nov 2015, Xenetic signed an Asset Purchase Agreement with Estonian biotech company, AS Kevelt and OJSC Pharmsynthez related to Virexxa. Under the terms of the agreement, the company received the worldwide rights to develop, market and license Virexxa for all uses, except for certain uses within the Commonwealth of Independent States (CIS).
As per the company’s press release, over 60,050 patients are diagnosed with endometrial cancer each year in the U.S. Moreover, about 10,470 deaths occur from the disease, representing about 1.8% of all cancer-related deaths in the U.S.
Investors looking for a well-placed stock in the health care sector may consider Actelion Ltd. , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Xenetic's IND to Start Phase II Virexxa Study Accepted in U.S.
Xenetic Biosciences, Inc. (XBIO - Free Report) announced that the FDA has accepted the company’s Investigational New Drug (IND) application to initiate a phase II study on Virexxa (sodium cridanimod) in endometrial cancer.
The study will evaluate Virexxa, in conjunction with progestin therapy, for the treatment of endometrial cancer in women with recurrent or persistent disease who have failed progestin monotherapy.
The primary objective of the study is the assessment of anti-tumor activity of Virexxa, while secondary objectives include the evaluation of additional efficacy, pharmacokinetic and safety/tolerability parameters of the candidate.
Note that, Virexxa is currently being evaluated in phase II study in patients with documented evidence of progesterone receptor-negative endometrial cancer as determined by tumor biopsy. The candidate enjoys Orphan drug status in the U.S. for the treatment of progesterone receptor-negative endometrial cancer.
XENETIC BIOSCI Price
XENETIC BIOSCI Price | XENETIC BIOSCI Quote
We remind investors that in Nov 2015, Xenetic signed an Asset Purchase Agreement with Estonian biotech company, AS Kevelt and OJSC Pharmsynthez related to Virexxa. Under the terms of the agreement, the company received the worldwide rights to develop, market and license Virexxa for all uses, except for certain uses within the Commonwealth of Independent States (CIS).
As per the company’s press release, over 60,050 patients are diagnosed with endometrial cancer each year in the U.S. Moreover, about 10,470 deaths occur from the disease, representing about 1.8% of all cancer-related deaths in the U.S.
Investors looking for a well-placed stock in the health care sector may consider Actelion Ltd. , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>